Valuation: Cohance Lifesciences Limited

Capitalization 16TCr 166.43Cr 143.17Cr 130.89Cr 123.86Cr 228.87Cr 232.66Cr 1.55TCr 607.4Cr 7.57TCr 624.51Cr 611.15Cr 26TCr P/E ratio 2027 *
58.6x
P/E ratio 2028 * 41.1x
Enterprise value 16TCr 166.79Cr 143.48Cr 131.17Cr 124.13Cr 229.37Cr 233.17Cr 1.55TCr 608.72Cr 7.59TCr 625.86Cr 612.47Cr 27TCr EV / Sales 2027 *
6.41x
EV / Sales 2028 * 5.06x
Free-Float
36.04%
Yield 2027 *
-
Yield 2028 * -
1 day-1.91%
1 week-13.31%
Current month-13.06%
1 month+7.58%
3 months+33.34%
6 months-27.84%
Current year-20.52%
1 week 391.05
Extreme 391.05
466.95
1 month 355.05
Extreme 355.05
514.9
Current year 266.7
Extreme 266.7
526.1
1 year 266.7
Extreme 266.7
1,121.15
3 years 266.7
Extreme 266.7
1,360
5 years 266.7
Extreme 266.7
1,360
10 years 87.6
Extreme 87.6
1,360
Manager TitleAgeSince
Director of Finance/CFO 32 02/01/2024
Compliance Officer 48 09/04/2026
Compliance Officer - -
Director TitleAgeSince
Director/Board Member - 29/09/2023
Director/Board Member 68 29/09/2023
Director/Board Member 63 29/09/2023
Change 5d. change 1-year change 3-years change Capi.($)
-1.91%-13.31%-60.68%-11.43% 169.26Cr
-0.25%+2.93%+34.93%+130.32% 91TCr
-0.30%+2.26%+50.38%+44.31% 55TCr
-0.68%+2.14%+14.32%+46.30% 38TCr
-0.42%+2.05%+26.19%+13.82% 33TCr
+0.50%+1.47%+34.50%+16.15% 29TCr
-0.42%+2.28%+29.48%+30.97% 29TCr
-1.09%+0.56%+46.32%-2.16% 28TCr
+0.31%-2.73%-34.26%-49.84% 20TCr
+0.25%-1.40%+20.20%+48.41% 18TCr
Average -0.40%+0.70%+16.14%+26.69% 34.11TCr
Weighted average by Cap. -0.28%+2.14%+29.92%+51.90%

Financials

2027 *2028 *
Net sales 2.51TCr 26Cr 22Cr 20Cr 19Cr 36Cr 36Cr 242.64Cr 95Cr 1.18TCr 98Cr 96Cr 4.14TCr 3.11TCr 32Cr 28Cr 25Cr 24Cr 44Cr 45Cr 299.91Cr 117.42Cr 1.46TCr 120.72Cr 118.14Cr 5.11TCr
Net income 277.57Cr 2.87Cr 2.47Cr 2.26Cr 2.14Cr 3.95Cr 4.02Cr 27Cr 10Cr 130.74Cr 11Cr 11Cr 456.7Cr 395.41Cr 4.09Cr 3.52Cr 3.22Cr 3.05Cr 5.63Cr 5.72Cr 38Cr 15Cr 186.24Cr 15Cr 15Cr 650.57Cr
Net Debt 35Cr 36.06L 31.02L 28.36L 26.84L 49.59L 50.41L 3.36Cr 1.32Cr 16Cr 1.35Cr 1.32Cr 57Cr -366.71Cr -3.8Cr -3.27Cr -2.99Cr -2.83Cr -5.22Cr -5.31Cr -35Cr -14Cr -172.72Cr -14Cr -14Cr -603.36Cr
Logo Cohance Lifesciences Limited
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based company focused on global contract development and manufacturing organization (CDMO) platform. The Company specializes in providing end-to-end solutions across the molecule's lifecycle from early-stage development to large-scale commercialization- with a marquee customer base across pharmaceuticals and specialty chemicals. It offers a platform for the lifecycle of small molecule active pharmaceutical ingredient (API) development and manufacturing. Its Integrated Small Molecule Solutions offers good manufacturing practice (GMP)-grade manufacturing solutions and provides small molecule APIs, advanced intermediates and starting materials. Its APIs commercial product line includes Aripiprazole, Articaine HCl, Atomoxetine HCl, Baclofen, Benserazide, Betahistine DiHCl and others. Its pipeline products include Apixaban, Acotiamide, Dexlansoprazole, Edoxaban, Erdosteine, and others.
Employees
1,212
Date Price Change Volume
20/26/20 420.15 -1.91% 11,69,486
19/26/19 428.35 +0.07% 1,02,13,860
18/26/18 428.05 +1.15% 39,65,401
15/26/15 423.20 -4.94% 14,76,684
14/26/14 445.20 -2.43% 14,63,411
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
420.15INR
Average target price
516.78INR
Spread / Average Target
+23.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. COHANCE Stock